Endocrine Abstracts

Gonadotropin-releasing hormone analogues (GnRHa) are prescribed to adolescents with gender dysphoria under age 15 who have reached Tanner stage 2/3 to prevent progression through puberty and allow them time to consider their gender identity. The possible effects of the therapy on the pubertal growth spurt are poorly understood. A height more congruent with their identified gender is desired by transgender individuals, thus it is crucial that they are fully informed of its pote...